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Abstract 
Purpose: A real-time in vivo dosimetric verification method using metal-oxide-semiconductor field effect 
transistor (MOSFET) dosimeters has been developed for patient dosimetry in high-dose rate (HDR) 
intracavitary brachytherapy of nasopharyngeal carcinoma (NPC). Methods: The necessary calibration and 
correction factors for MOSFET measurements in 192Iridium source were determined in a water phantom. 
With the detector placed inside a custom-made nasopharyngeal applicator, the actual dose delivered to 
the tumor was measured in vivo and compared to the calculated values using a commercial 
brachytherapy planning system. Results: Five MOSFETs were independently calibrated with the HDR 
source, yielding calibration factors of 0.48 ± 0.007 cGymV. The maximum sensitivity variation was no 
more than 7 in the clinically relevant distance range of 1-5 cm from the source. A total of 70 in vivo 
measurements in 11 NPC patients demonstrated good agreement with the treatment planning. The mean 
differences between the planned and the actually delivered dose within a single treatment fraction were 
-0.1 ± 3.8 and -0.1 ± 3.7, respectively, for right and left side assessments. The maximum dose deviation 
was less than 8.5. Conclusions: In vivo measurement using the real-time MOSFET dosimetry system is 
possible to evaluate the actual dose to the tumor received by the patient during a treatment fraction and 
thus can offer another line of security to detect and prevent large errors. 
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[Purpose]: A real-time in vivo dosimetric verification method using 
metal-oxide-semiconductor field effect transistor (MOSFET) dosimeters has been 
developed for patient dosimetry in high dose rate (HDR) intracavitary brachytherapy 
of nasopharyngeal carcinoma (NPC). 
[Materials and Methods]: The necessary calibration and correction factors for 
MOSFET measurements in 
192
Iridium source were determined in a water phantom. 
With the detector placed inside a custom-made nasopharyngeal applicator, the actual 
dose delivered to the tumor was measured in vivo and compared to the calculated 
values using a commercial brachytherapy planning system (BPS).  
[Results]: The mean calibration factor between each MOSFET detector in 
192
Iridium 
source was 0.48±0.007 cGy/mV. The maximum sensitivity variation was no more 
than 7% in the clinically relevant distance range of 1 to 5 cm from the source. A total 
of 70 in vivo measurements in 11 NPC patients demonstrated good agreement with the 
treatment planning. The mean differences between the planned and the actually 
delivered dose within a single treatment fraction were -0.1%±3.8% and -0.1%±3.7%, 
respectively, for right and left side assessments. Corresponding values obtained after 
averaging results over all fractions of a patient were -0.2%±3.9% (right side) and 
-0.3%±3.7% (left side). The maximum dose deviation was less than 8.5%.  
[Conclusion]: In vivo measurement using the real-time MOSFET dosimetry system is 
possible to evaluate the actual dose to the tumor received by the patient during a 
treatment fraction and thus can offer another line of security to detect and prevent 
large errors.  
KEYWORDS:  MOSFET, in vivo dosimetry, real time dosimetry, intracaviatry 
brachytehrapy, quality assurance 
 
Introduction 
The recent evolution of computed tomography (CT)-based implant planning and 
dosimetry has sparked renewed interest in using high-dose rate (HDR) intracavitary 
brachytherapy for the treatment of nasopharyngeal carcinoma (NPC) [1, 2]. The 
CT-based techniques have accurately reconstructed the position of all intracavitary 
applicators with respect to the patient’s anatomy, thereby demonstrating the spatial 
dose distributions to the tumor volume and neighboring structures. By optimizing the 
relative dwell times for each activated dwell position, the radiation doses are best 
conformed to the NPC whilst sparing more of the normal tissues like brain stem, 
spiral cord, temporary lobes, visual apparatus and pituitary gland [3]. 
However, when HDR brachytherapy is used, the treatments must be executed very 
carefully. A number of factors could potentially lead to substantial dose deviations 
from the prescription in the chain of HDR treatment [4]. This is mainly due to the fact 
that the planning and treatment systems tend to be relatively complicated. Significant 
errors in treatment dose can result from the use of incorrect calculation parameters as 
well as from machine malfunction [4-7]. As it has been pointed out recently [5], these 
potential errors are quite difficult to be identified and even though all the quality 
assurance (QA) checks recommended have been implemented, mistakes can happen 
without detection. This may result in severe radiation injury to patients since HDR 
brachytherapy delivers very high doses within a short time period. To avoid therapy 
misadministration as well as to verify the actual doses delivered to the tumor during 
 
an HDR treatment, the development of an in vivo dosimetry method as a supplement 
to existing QA programs is thus very desirable.  
 Several studies have explored the feasibility of in vivo dosimetry with 
thermoluminescent dosimeters (TLDs) and semiconductor diodes for HDR 
brachytherapy [5, 8-10]. While TLDs are often used in clinical dosimetry due to their 
small size, they are also known to be tedious to use [11, 12]. The fact that acquiring 
moderately accurate, reproducible results using TLDs requires stringent calibration, 
handling and annealing procedures suggests that in vivo thermoluminescence 
dosimetry would be difficult to implement on a daily basis. Also TLDs are not real 
time dosimeters so that they are incompetent to provide on-line monitoring of 
operational mistakes and their immediate corrections. Semiconductor diodes are 
simpler to use than TLDs. The major disadvantages of diodes are their relatively large 
size, which makes them unable to be held in a small nasopharyngeal applicator. In 
addition, some investigations have revealed that diode measurements may need 
several correction factors for even simple application in clinical radiotherapy [13, 14]. 
 The MOSFET detector is the most recent development for in vivo dosimetry 
compared with TLDs and diodes. Incorporating many of the advantages of TLDs and 
diodes such as small physical size, ease of use and immediate readout, the MOSFET 
has demonstrated their potential use in HDR brachytherapy [15-17]. In a previously 
published study, Zilio and his coworkers proved that the MOSFET detector, with 
appropriate calibration and correction, could also be used for absolute dosimetry in 
 
the context of a microSelectron HDR 
192
Ir source, even for situations where photon 
energy spectra were different from the reference location [15]. More recently, our 
group has successfully exploited an improved micro-MOSFET design with reduced 
external dimensions for use in brachytherapy catheters as a means of routine QA to 
verify brachytherapy dose calculations [16]. These pilot MOSFET dosimetry studies, 
basically, are limited to the integral dose measurements, in which results are obtained 
only after a treatment has been delivered. As reported by Gladstone et al [18] and 
others [19, 20], the MOSFET detector has an advantage over many other dosimeters 
in its ability to provide real-time dose information. This will offer extra benefits for 
treatment monitoring in that it may allow dose errors to be detected at a much earlier 
stage.  
The main purpose of the present study is to provide a real time MOSFET 
dosimetry system in avoiding therapy misadministration for HDR intracavitary 
brachytherapy. The reproducibility of MOSFET measurements in real time mode was 
investigated. The preliminary results of real-time in vivo measurements with 
MOSFET detectors for 70 treatment fractions in 11 NPC patients are presented.  
Materials and Methods 
Nasopharyngeal applicator 
HDR intracavitary brachytherapy treatments were generally delivered with two 
customized nasopharyngeal applicators at our institutions, one in each naris, with a 
 
separation of 1.2-1.5 cm according to the size of the tumor target. 
The nasopharyngeal applicator (Figure 1) is a thermoplastic resin tube with a 
curvature of about 20° at 1 cm from the distal blind end. It has an outer diameter of 
2.0 mm and an inner diameter of 1.8 mm, which can accommodate standard 6 French 
afterloading catheters. The applicator can be reshaped for each individual patient, 
when heated, to conform to the superoposterior wall of the nasopharynx. Thus the 
HDR 
192
Iridium stepping source can be positioned closer to the target mucosa as 
compared with the traditional intraluminal stabilizing devices which place the source 
in the middle of the cavity and hence up to 1-2 cm from the target mucosa [3].  
The customization process for the nasopharyngeal applicator is performed under 
topical anesthesia using nebulized 4% lidocaine hydrochloride applied to the patient’s 
nasal cavity, nasopharynx, and oropharynx. With the guidance of a nasopharyngeal 
speculum, the applicator is introduced 
 
 
Figure 1 A custom-made nasopharyngeal applicator. The imprinted lengths and angles 
on the applicator are used for daily applicator positioning.  
 
 transnasally into the nasopharynx and is custom formed to be optimally 
positioned against the region of the primary disease. The nasopharyngeal applicator is 
then secured to the nose by a thermoplastic mask. The inserted length and orientation 
to the nasopharyngeal cavity are recorded accordingly from graduations and angles 
imprinted on the applicator to allow the applicator position to be reproduced in the 
subsequent treatments.  
MOSFET dosimetry system 
The applied MOSFET dosimetry system, including the recently developed 
micro-MOSFET detectors (MOSkin
TM
) and a microprocessor based reader, has been 
previously introduced [16, 21]. One of the major characteristics of this 
micro-MOSFET detector is its packaging technology, by which the sensor chip is 
hermetically sealed with a 70-µm thick water-equivalent film. The thin-film 
encapsulating layer prevents damage to the electronics, and acts as a carrier of the thin 
aluminum contact leads that are connected to the MOSFET sensor from the top-side.  
In this experiment, dose measurements were performed in a real time mode with 
 
a positive bias voltage of 5 V applied to the MOSFET during irradiation. This 
required a connection to a laptop computer and utilization of the “MosPlot” software. 
The computer data acquisition system measured periodically the instantaneous 
voltage signal with the user-defined period (one second in this case). The software 
MosPlot 4.2 allowed for the online graphical presentation of the change in the 
threshold voltage Vth (i.e. accumulated dose variation) or increments of ⊿Vth for 
consecutive readouts (i.e. differential dose rate).  
MOSFET calibration and correction 
The calibration process is essentially a two-step process: calibration in a standard 
set-up to determine the reference calibration factor and subsequently the 
establishment of a series of correction factors for irradiation conditions deviating from 
the reference conditions.  
Five MOSFET detectors were independently calibrated against a NE-2571 0.6 
cm
3
 Farmer-type ionization chamber (Nuclear Technology Ltd., Reading, UK) in a 30
×30×30 cm3 water phantom. Following the recommendations for ionization 
dosimetry around the 
192
Iridium source, a reference point at a perpendicular distance 
of 5 cm from the source was selected [22]. By using a template calibration jig, the 
dose in water at the reference point was measured with the ionization chamber and the 
MOSFET detector, respectively. To improve the measurement accuracy, a radiation 
dose of 50 cGy was delivered to the MOSFET detector every time, which was 
sufficient to ensure that the response uncertainty associated with the MOSFET reader 
 
would equate to less than 1% of the threshold voltage change. The calibration factor, 
in terms of cGy per mV, was therefore determined for each individual MOSFET.  
To overcome the MOSFET sensitivity variation with the energy spectrum in 
192
Iridium brachytherapy, an energy dependent correction factor, CF, was introduced 
for measurement performed at locations other than the calibration position. The CFs, 
defined as the inverse of MOSFET sensitivities, were measured at five 
source-to-detector distances ranging from 1 cm to 5 cm with 1 cm increment along the 
source transverse bisector axis in the water phantom [16]. The derived CF factors 
were fitted with a least-squares polynomial, whereby the CFs for other positions 
between 1 cm and 5 cm could be obtained by interpolation. The determined energy 
dependent correction factors were compared with the published data for a previously 
used RADFET dosimeter. 
The reproducibility of real-time MOSFET dosimetry system 
Since the introduction of the automatic data acquisition system in the real time 
mode may add electronic noise to the signal, the readout reproducibility of the 
MOSFET dosimetry system in the real time mode was investigated at different dose 
levels and was compared with dosimeter readings being manually triggered. 
  Under the calibration set-up, the MOSFET detector was irradiated ten times for 
each of the following integrated doses: 20, 30, and 50 cGy. The threshold voltage 
change before and after each irradiation was measured using both the real-time mode 
 
and the manual mode. The corresponding coefficients of dispersion of repeated 
measurements were computed for different applied doses.  
CT-based HDR intracavitary brachytherapy 
 HDR intracavitary brachytherapy provided an attractive method of boosting dose 
to NPC whilst sparing sensitive normal tissues. Prior to the CT simulation, the 
nasopharyngeal applicators were brought into the nasopharynx under the direct 
guidance of the nasopharyngeal speculum and remained in situ for the duration of the 
treatment. The patient was then laid on the simulator table, immobilized with a head 
and neck mask in the supine position. Three radiopaque markers were attached to the 
mask in alignment with the CT lasers, which served as benchmarks for daily 
radiographs to verify the applicator localization. After insertion of standard 
afterloading catheters with dummy sources into the nasopharyngeal applicator, the 
patient was CT scanned with 1-mm slice thickness and 1-mm pitch. The acquired CT 
images were subsequently transferred to the Plato BPS (Nucletron, The Netherlands).  
 The primary tumor target and critical structures such as brainstem, spinal cord 
and bilateral parotid glands were contoured on all the involved CT slices. The two 
applicators were sequentially reconstructed by the BPS. A catheter offset value, which 
was predetermined in the CT scout view, was used for correctly placing the center of 
the first dwell position with respect to the reconstructed catheter. The minimal 
peripheral dose (MPD), typically 3-5 Gy per fraction, was prescribed to cover the 
target surface. A geometrical optimization was performed, followed by manually 
 
adjusting dwell weights and times to further improve the target dose uniformity.  
The dose rate that every source dwell position delivered to the measurement point 
where the MOSFET detector was located during the in vivo measurement was 
computed. This can be simply done by nulling all dwell times except for the selected 















&  is the dose rate delivered by source dwell position i to the measurement 
point; it  is the planned dwell times of source dwell position i and 00 =t . 
In vivo dosimetric verification  
The HDR treatments were delivered on an outpatient basis once per day for 2 to 4 
days. The applicator localization was verified with fluoroscopy each time and 
orthogonal radiographs were taken for document. 
The MOSFET detector was placed into one applicator fixing to its distal blind 
end, when the other applicator was being used to implement treatment and vice versa. 
Fixing the MOSFET to the distal blind end of the applicator may make the detector 
position reproducible with each fraction to the applicator. 
 After accurate positioning of the nasopharyngeal applicators and the MOSFET 
detector had been confirmed, the HDR treatment was performed sequentially for each 
 
applicator. The in vivo measurements were started as soon as the 
192
Iridium stepping 
source was driven out of the container. The accumulated threshold voltage of the 
MOSFET detector was recorded with the controlled software MosPlot 4.2 every 
second. By using a lookup table, the measured threshold voltage shift was converted 
to the absorbed dose, which was then compared with the calculated values by the 
BPS.  
To date, real-time in vivo dosimetry with MOSFET detectors has been performed 
for a total of 70 measurements of 11 NPC patients. For all the patients, measurements 
were followed through the whole treatment sessions.  
Results 
MOSFET calibration and correction 
Five MOSFET detectors were independently calibrated in the water phantom, 




 The energy dependent correction factors between the new micro-MOSFET 
detector and a previously used RADFET dosimeter provided by the same 




Figure 2 Comparison of energy-dependent correction factors between the new 
MOSkin
TM
 and a previously used RADFET dosimeter. The RADFET data were 
derived from the published data [8], which were re-normalized to the 5-cm value.  
 
 source axis distances. The RADFET data were derived from the published data [15], 
which were re-normalized to the 5-cm value. The newly developed micro-MOSFET 
detector showed a relatively flat energy response in the low energy spectrum of the 
192
Iridium source compared with the RADFET dosimeter. The maximum sensitivity 
variation was found to be no more than 7% in the given distance range.  
The reproducibility of real-time MOSFET dosimetry system 
 
As the radiation dose increased from 20 cGy to 50 cGy, the reproducibility of the 
dosimetry system was improved from 3.5% to 1.4% for the manual mode and from 
4.8% to 1.9% for the real-time mode (Table 1). A relatively large deviation in 
reproducibility tests associated with real-time data acquisition may be partially owing 
to electronic noise. However, for irradiated dose levels of more than 50 cGy, the 
real-time mode can also give a reasonable reproducibility of measurements better than 
2.0%. 
In vivo dosimetric verification 
In vivo dosimetric verification was performed for 70 measurements of 11 NPC 
patients. The residual position error of the nasopharyngeal applicators, observed from 
the verification films, was on average 1.6±0.6 mm in the right-left direction, 
0.7±0.3 mm in the cranial-caudal direction, and 0.8±0.3 mm in the 
anterior-posterior direction.  
Figure 3 was an example of real-time comparison of in vivo measurements with 
calculated accumulated dose variations for a given treatment fraction. The transit 
doses were included in the measurements. In low dose region (< 20 cGy), the 
maximum dose discrepancy between in vivo measurements and TPS calculations was 
less than 2 cGy. The MOSFET measurements coincided with the calculated values 
better than ±3.5% in high dose region (> 30 cGy). The measured total accumulated 
dose was found to be agreed with the planned dose within 1.1% in this case.  
 
The observed dose differences within a single treatment fraction were on average 
-0.1%±3.8% (right side) and -0.1%±3.7% (left side), as shown in Figure 4a and 4b. 
94% of right side measurements and 91% of left side  
 
Figure 3 An example of real time dose variations between in vivo measurements and 
calculated accumulated doses for a given treatment fraction. The MOSFET 




Figure 4 The frequencies of measurements with discrepancies in percentage between 
measured and calculated values for right and left side measurements, respectively. a: 
right side; b: left side. 
 
 
Figure 5 The discrepancies between measured and planned doses averaged over all fractions 
of a patient. The error bar represents one standard deviation.  
 
assessments have deviations within the range of -5% to 7%. The maximum dose 
discrepancy was 8.3%.  
The corresponding dose measurements with MOSFET detectors in each fraction 
of a particular patient were then averaged and compared with the expected BPS 
calculated dose. As plotted in Figure 5, the mean discrepancies between measured and 
planned doses averaged over all fractions of each patient was -0.2±3.9% (right side) 
and -0.3±3.7% (left side), respectively. All the patients received a total dose different 
from the prescription within the tolerance range of -5% to 7%.  
 
7.4.   Discussions 
 The widespread application of HDR brachytherapy with its inherent dangers 
necessitates a comprehensive set of QA programs to minimize risks to both patients 
and medical staff. Besides separate QA checks for each component of the treatment 
process, in vivo dosimetry which can provide an estimate of the overall error in an 
HDR treatment has been recommended by many authors [5, 6, 8-10].  
Due to the small physical size, the MOSFET detector can be conveniently 
introduced to the nasopharynx via the small nasopharyngeal applicator making it 
attractive for in vivo treatment verification. Before use each MOSFET detector should 
be calibrated individually against an ionization chamber in the water phantom. There 
are some reports that the radiation response of the MOSFETs may not completely 
linear over the whole voltage range [15, 17]. As a result, a recalibration of the device 
was performed periodically for every 5-V increment in our experiments.  
 The MOSFET detectors are known to have photon energy dependence in the low 
energy range of the 
192
Iridium spectrum [15, 23]. The previously published data 
showed that a correction factor of about 1.27 times greater than the 5-cm value was 
required in absolute depth dose determination at 1-cm distance from the source for a 
RADFET dosimeter [15]. In this updated generation products, the energy response of 
the MOSFET detector in the 
192
Iridium spectrum has been optimized by using special 
encapsulation techniques that avoid high Z materials close to the dosimetric volume. 
The sensitivity variation, as shown by our results, was minimized to be within 7% in 
 
the clinically relevant distance range of 1-5 cm. This will help improve the dosimetric 
accuracy of in vivo measurement for HDR brachytherapy.  
The reproducibility of MOSFET measurements in the manual mode was found to 
be 1.4% at the threshold voltage shift of about 100 mV. This result was consistent 
with previous findings [24]. Due to electronic noise, the real time data acquisition 
mode exhibited a relatively large deviation in reproducibility tests (i.e. 1.9%). 
Considering normal HDR treatments usually deliver a dose that can cause a threshold 
voltage change higher than 100 mV to the measurement point, it is practically within 
the measurement uncertainty.  
Among kinds of QA problems for HDR brachytherapy, the accurate placement of 
the applicator is crucial for reliable dose distribution and treatment outcome. Kremer 
et al developed a computer-assisted device for three-dimensional placement of 
afterloading probes based on CT scans [25]. With this device, target points have been 
reached with a mean accuracy of 0.6 mm (maximum deviation was 2.6 mm). At our 
institution, we treated NPC patients using a customized nasopharyngeal applicator on 
an individual basis as introduced by Ng et al [3]. By improving the applicator design 
with the indicated lengths and angles as well as immobilizing the patient head and the 
applicator with a face mask, the inaccuracy of applicator positioning can be 
minimized to the same level as the complex computer-assisted system. The 
preliminary results from a total of 70 in vivo measurements with real time MOSFET 
dosimetry show good agreement between theory and experiment. The observed mean 
 
differences between the actually delivered and the planned dose within a single 
treatment fraction were -0.1±3.8% and -0.1±3.7%, respectively, for right and left 
side assessments. More research is warranted. 
 Unlike standard fractionated radiation therapy, the HDR treatment delivers a very 
high dose over a few fractions. In such condition, real time dosimetry is most valuable 
in detecting a dose error at the onset of treatment and providing the capability of 
immediate corrections. According to the previously published document [5], more 
than 20% total dose deviation from prescription was taken as our action level to avoid 
“significant errors”. However, for a treatment with measurable 10%～20% dose 
difference, a retrospective QA review was also required. By means of online 
comparison between measured doses and calculated values, the validity of HDR 
treatment was ensured. The measured average dose over all fractions of a patient 
differed from the calculated value all within -5% to 7% in our experiment.  
 The presented study has major focus on the development of a simple point dose 
method for in vivo monitoring and verification of HDR treatments. Hence only a 
single MOSFET detector was evaluated in our phantom measurements and in vivo 
applications. Price and his coworkers have recently presented a new linear 
MOSFET-array dosimeter configuration that can provide a one-dimensional dose 
profile across the target volume [26]. As the detector array may better serve the 
purpose of in vivo patient dosimetry, it is now under research by ours and other 
groups. In future developments the external dimensions of the array dosimeter will be 
 
significantly reduced so as to permit its use in brachytherapy applicators. Anyhow, we 
feel that even with currently designed MOSFETs, the proposed method is capable of 
detecting errors of major clinical significance.  
Conclusion 
In vivo measurement using the real-time MOSFET dosimetry system provides a 
means of overall dosimetry check for the HDR treatment. With detectors placed 
within the patients’ nasopharynx, it is possible to evaluate and document, in real time, 
the actual dose to the tumor received by the patient during a treatment fraction.  
Through an online comparison between the measured dose and the calculated value, 
the dosimetry system offers another line of security to detect and prevent large errors. 
The method we presented here is universal and can be applied in any other cases of 
clinical interest.  
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Table 1 The MOSFET readout reproducibility in different data acquisition modes at given 
dose levels.  
MOSFET readout reproducibility Dose level  
(cGy) Manual mode Real time mode 
20 3.5% 4.8% 
30 2.4% 3.2% 
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Figure 1 A custom-made nasopharyngeal applicator. The imprinted lengths and angles 
on the applicator are used for daily applicator positioning.  
Figure 2 Comparison of energy-dependent correction factors between the new 
MOSkin
TM
 and a previously used RADFET dosimeter. The RADFET data were 
derived from the published data [8], which were re-normalized to the 5-cm value. 
Figure 3 An example of real time dose variations between in vivo measurements and 
calculated accumulated doses for a given treatment fraction. The MOSFET 
measurements coincided with the calculated values throughout the treatment delivery.  
Figure 4 The frequencies of measurements with discrepancies in percentage between 
measured and calculated values for right and left side measurements, respectively.  
Figure 5 The discrepancies between measured and planned doses averaged over all 
fractions of a patient. The error bar represents one standard deviation. 
 
